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In vitro investigations of immunological reactivity in sarcoidosis have revealed both quantitative and qualitative abnormalities in the immune system. Lymphopenia has been reported as a feature in a high percentage of patients (Hoffbrand, 1968) , and the mean total lymphocyte count of groups of sarcoidosis patients has been shown to be significantly lower than that of control groups (Hedfors, Holm, and Pettersson, 1974; Ramachandar et al., 1975) . Studies on lymphocyte subpopulations have shown that the lymphopenia is due to a selective reduction in thymus derived lymphocytes (T cells) responsible for cellular immune responses while 'Bursa' derived lymphocytes (B cells) responsible for humoral immunity have been found to be present in normal or increased numbers (Hedfors et al., 1974; Mangi et al., 1974a; Ramachandar et al., 1975 Wybran, Carr, and Fundenberg, 1972 ) and a fluorescent antibody technique for the identification of immunoglobulin bearing cells (B cells) (Papamichail, Brown, and Holborow, 1971; Brown and Greaves, 1974 Table III .
DISCUSSION
The results of this study show that sarcoidosis patients as a group have a lower mean total lymphocyte count than normal controls. They also have a significantly lower T cell count while there was no significant difference in the absolute numbers of B cells or null cells between the two groups. Analysis of lymphocyte subpopulations in the clinical subgroups shows that there is no significant difference in the groups selected for stage, activity, treatment programme or duration of the disease. These results confirm those of several other workers ; (Hoffbrand, 1968; Hedfors et al., 1974; Ramachandar et al., 1975 ). There appears to be general agreement on the reduced total lymphocyte count and T cell count in sarcoidosis patients but an elevated mean B cell count has been previously reported (Ramachandar et al., 1975) although we did not find this in the present study in agreement with other reports (Hedfors et al., 1974; Mangi et al., 1974a (Mangi et al., 1974a; Ramachandar et al., 1975) . This underlines the importance of technical factors in different surveys which make direct comparison difficult. Other problems encountered on comparing different studies on sarcoidosis patients include the variability of the disease process under investigation both within a country and between countries (Hall et al., 1969; Siltzbach et al., 1974) .
The failure to demonstrate differences between sarcoidosis patients selected for stage, activity, treatment regime, and duration of the disease process is at variance with some previous reports.
A lower total lymphocyte count was found in patients with long-standing disease than in those of recent onset (Hoffbrand, 1968; Hedfors et al., 1974) . A lower T cell count was found in patients receiving corticosteroid therapy than in those not receiving such therapy (Mangi et al., 1974a (Hedfors, 1975; Ramachandar et al., 1975) . The significance of the observed abnormalities remains to be elucidated. The reduced T cell count in sarcoidosis patients may reflect decreased production or increased 'utilization'. Circulating inhibitors have been identified in sarcoidosis patients which reduced lymphocyte responsiveness to mitogens (Belcher, Carney, and Nankervis, 1974; Mangi, Dwyer, and Kantor, 1974b) . A similar mechanism may be involved in the quantitative reduction in T cells. It has been suggested that lymph node involvement by the disease process may impair recirculation of T lymphocytes contributing to the lower T cell counts (Ramachandar et al., 1975) .
The results of the present study and others indicate that these investigations are of limited value in the management of individual patients with sarcoidosis. The observed abnormalities in this study fail to correlate with the clinical features of sarcoidosis in groups of patients. The value of sequential analysis in individual patients remains to be assessed.
